Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021. (20th November 2020)

• Record Type: Journal Article
• Authors: Demel, Ivo; Bago, Julio Rodriguez; Hajek, Roman; Jelinek, Tomas
• Is Part Of: British journal of haematology. Volume 193:Number 4(2021)
• Page Start: 705
• Page End: 722
• Publication Date: 2020-11-20
• Subjects: multiple myeloma -- BCMA -- bispecific antibodies -- antibody‐drug conjugates -- belantamab mafodotin; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.17235
• Languages: English
• ISSNs: 0007-1048

Abstract

Abstract: Remarkable advances have been achieved in the treatment of multiple myeloma (MM) in the last decade, which saw targeted immunotherapy, represented by anti‐CD38 monoclonal antibodies, successfully incorporated across indications. However, myeloma is still considered curable in only a small subset of patients, and the majority of them eventually relapse. B‐cell maturation antigen (BCMA) is expressed exclusively in mature B lymphocytes and plasma cells, and represents an ideal new target for immunotherapy, presented by bispecific antibody (bsAb) constructs, antibody‐drug conjugates (ADCs) and chimeric antigen receptor T (CAR‐T) cells. Each of them has proved its efficacy with the potential for deep and long‐lasting responses as a single agent therapy in heavily pretreated patients. As a result, belantamab mafodotin was approved by the United States Food and Drug Administration for the treatment of relapsed/refractory MM, as the first anti‐BCMA agent. In the present review, we focus on monoclonal antibodies targeting BCMA – bsAbs and ADCs. The data from preclinical studies as well as first‐in‐human clinical trials will be reviewed, together with the coverage of their constructs and mechanisms of action. The present results have laid the groundwork for the ongoing or upcoming clinical trials with combinatory regimens, which have always been a cornerstone in the treatment of MM.